Urso
Company: Axcan Schwarz
Approval Status: Approved December 1997
Treatment for: primary biliary cirrhosis
Areas: Gastroenterology
| General Information | Clinical Results |
General Information
Other Useful Resources
Urso has been approved for the treatment of primary biliary cirrhosis.
Clinical Results
The approval rested primarily on the results of two Phase III trials conducted in approximately 300 patients. A two-year 180-patient study performed by the Mayo Clinic dosed patients at 13-15 mg/kg per day with Urso tablets 250 mg four times daily. Among patients receiving Urso, 23% were considered treatment failures compared to 47% in the placebo group.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
